Autor: |
Kalu, Ibukunoluwa C, Zimmerman, Kanecia O, Goldman, Jennifer L, Mast, Dana Keener, Blakemore, Ashley M, Moorthy, Ganga, Boutzoukas, Angelique E, Campbell, Melissa M, Uthappa, Diya, DeLaRosa, Jesse, Potts, Jessica M, Edwards, Laura J, Selvarangan, Rangaraj, Benjamin, Daniel K, Mann, Tara K, Schuster, Jennifer E |
Předmět: |
|
Zdroj: |
Journal of the Pediatric Infectious Diseases Society; Feb2023, Vol. 12 Issue 2, p64-72, 9p |
Abstrakt: |
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) screening testing is a recommended mitigation strategy for schools, although few descriptions of program implementation are available. Methods Kindergarten through 12th grade (K–12) students and staff practicing universal masking during the delta and omicron variant waves from five schools in Durham, North Carolina and eight schools in Kansas City, Missouri participated; Durham's program was structured as a public health initiative facilitated by school staff, and Kansas City's as a research study facilitated by a research team. Tests included school-based rapid antigen or polymerase chain reaction testing, at-home rapid antigen testing, and off-site nucleic acid amplification testing. Results We performed nearly 5700 screening tests on more than 1600 K–12 school students and staff members. The total cost for the Durham testing program in 5 public charter K–12 schools, each with 500–1000 students, was $246 587 and approximately 752 h per semester; cost per test was $70 and cost per positive result was $7076. The total cost for the Kansas City program in eight public K–12 schools was $292 591 and required approximately 537 h in personnel time for school-based testing; cost per test was $132 and cost per positive result was $4818. SARS-CoV-2 positivity rates were generally lower (0–16.16%) than rates in the community (2.7–36.47%) throughout all testing weeks. Conclusions and Relevance Voluntary screening testing programs in K–12 schools are costly and rarely detect asymptomatic positive persons, particularly in universally masked settings. Clinical Trial Registration NCT04831866. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|